Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-904-8 | CAS number: 53988-10-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
MBI (2-Mercaptobenzimidazole) and the MMBIs [4-methylated MBI (4-MMBI)
and 5-methylated MBI (5-MMBI), and a 1:1 mixture of these 4- and
5-methylated isomers (MMBI mix)] suspended in corn oil were repeatedly
administered (at 0.3–0.6 mmol/ kg) to male Wistar rats by gavage once
daily for 2 weeks. After the first and last administrations, blood and
urine samples were collected, and the levels of unchanged compounds and
their desulfurated metabolites were determined.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
The toxicokinetik of 2-mercaptomethylbenzimidazole (MMBI) in rats was examined in several studies and compared with the toxikokinetik profile of 2-mercaptobenzimidazole (MBI).Additionally the metabolites of MMBI and MBI were examined in urine.
MMBI in serum disappeared faster than MBI, being undetectable even at 12 hr at 50 mg/kg. When 4-MMBI and 5-MMBI were determined separately after oral administration of MMBI at 50 mg/kg, the former disappeared slower than the latter, indicating the apparent effect of the position of methyl substituent on the toxicokinetics of MMBI.
MBI and MMBI (2-mercaptomethylbenzimidazole) showed similar Cmax values, but the former disappeared slower in the serum than the latter and resulted in its larger AUC values. Analyses of MBI, MMBI and their desulfurated metabolites in urine suggested that these differences were due to their metabolic elimination rates. As desulfurated metabolites of MMBI the 5-MeBI (5-methylbenzimidazole) and 4-MeBI (4-methylbenzimidazole) were identified.
Discussion on bioaccumulation potential result:
After repeated oral administration (roa), the Cmax and area under concentration-time curve (AUC) of MBI were markedly increased, while the MMBIs essentially were cleared from the blood within 10 h. After roa, the Cmax and AUC of 4-MMBI decreased markedly, suggesting metabolic enzyme induction. However, the toxicokinetic parameters of 5-MMBI were not markedly altered by roa.
After roa of 0.6 mmol/kg of the MMBI mix, urinary excretion of unchanged compounds, 4-MMBI and 5-MMBI, on day 15 increased markedly (7-fold and 2-fold of those amounts on day 1, respectively). In contrast, the urinary excretion of their desulfurated metabolites was not altered significantly. Roa of the lower dose (0.3 mmol/kg) did not affect urinary excretion patterns. The sum of the urinary excretions of unchanged compounds and their desulfurated metabolites during the 24 h following oral administration of these thioureylene compounds was less than 10% of the administered amounts. When administered each isomer separately, urinary excretion of the desulfurated metabolite, 4-MeBI, on day 14 was increased 2-fold (P<0.01) by roa of 4-MMBI compared with that on day 1. However, in the case of 5-MMBI, urinary excretion of both the unchanged compound and the desulfurated metabolite, 5-MeBI, were not altered by roa.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
